Workflow
Karyopharm Therapeutics(KPTI)
icon
Search documents
Karyopharm Therapeutics(KPTI) - 2022 Q3 - Earnings Call Transcript
2022-11-04 02:18
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Elhan Webb - Senior Vice President-Investor Relations Richard Paulson - President & Chief Executive Officer Sohanya Cheng - Chief Commercial Officer Reshma Rangwala - Chief Medical Officer Mike Mason - Chief Financial Officer Conference Call Participants Kevin Strang - Jefferies Abi Gray - R.W. Baird Brian Abrahams - RBC Capital Markets Eric Joseph - JPMorgan Operator Good afternoon. ...
Karyopharm Therapeutics(KPTI) - 2022 Q3 - Earnings Call Presentation
2022-11-03 23:33
1 ©2022 KARYOPHARM THERAPEUTICS INC. Third Quarter 2022 Financial Results & Business Update November 3, 2022 On Today's Call • Welcome Elhan Webb, CFA, Senior Vice President, Investor Relations • Overview Richard Paulson, President and Chief Executive Officer • Commercial Highlights Sohanya Cheng, Chief Commercial Officer • Pipeline Update Dr. Reshma Rangwala, Chief Medical Officer • Financial Summary and Guidance Michael Mason, Chief Financial Officer • Closing Remarks Richard Paulson, President and Chief ...
Karyopharm Therapeutics(KPTI) - 2022 Q3 - Quarterly Report
2022-11-03 20:28
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Karyopharm Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 26-393 ...
Karyopharm Therapeutics(KPTI) - 2022 Q2 - Quarterly Report
2022-08-04 20:29
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Karyopharm Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 26-3931704 ...
Karyopharm Therapeutics(KPTI) - 2022 Q2 - Earnings Call Transcript
2022-08-04 15:49
Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) Q2 2022 Results Conference Call August 4, 2022 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Mike Mason - EVP, CFO & Treasurer Reshma Rangwala - Chief Medical Officer Conference Call Participants Kevin Strang - Jefferies Peter Lawson - Barclays Mike Ulz - Morgan Stanley Colleen Kusy - Baird Eric Joseph - JP Morgan Ed White - H.C Faisal Khurshid - SVB Securities Operat ...
Karyopharm Therapeutics (KPTI) Investor Presentation - Slideshow
2022-06-03 18:37
1 ©2022 KARYOPHARM THERAPEUTICS INC. May 2022 A Commercial-Stage Pharmaceutical Company Pioneering Novel Cancer Therapies Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's guidance on its 2022 net product revenue and 2022 non-GAAP research and development and selling, general and administrative expenses ...
Karyopharm Therapeutics (KPTI) Investor Presentation - Slideshow
2022-05-18 13:43
1 ©2022 KARYOPHARM THERAPEUTICS INC. May 2022 A Commercial-Stage Pharmaceutical Company Pioneering Novel Cancer Therapies Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's guidance on its 2022 net product revenue and 2022 non-GAAP research and development and selling, general and administrative expenses ...
Karyopharm Therapeutics(KPTI) - 2022 Q1 - Earnings Call Presentation
2022-05-13 03:33
1 ©2022 KARYOPHARM THERAPEUTICS INC. First Quarter 2022 Financial Results & Business Update May 5, 2022 On Today's Call • Welcome Elhan Webb, Senior Vice President, Investor Relations • Overview Richard Paulson, President and Chief Executive Officer • Commercial Highlights Sohanya Cheng, Chief Commercial Officer • Pipeline Update Dr. Reshma Rangwala, Chief Medical Officer Dr. Patricia Judson, Senior Vice President, Medical Strategy • Financial Summary and Guidance Michael Mason, Chief Financial Officer • Cl ...
Karyopharm Therapeutics(KPTI) - 2022 Q1 - Earnings Call Transcript
2022-05-06 01:38
Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Michael Mason - EVP, CFO & Treasurer Reshma Rangwala - Chief Medical Officer Patricia Judson - SVP, Medical Strategy Conference Call Participants Maurice Raycroft - Jefferies Peter Lawson - Barclays Bank Michael Ulz - Morgan Stanley Faisal Khurshid - SVB Leerink Edward White - H ...
Karyopharm Therapeutics(KPTI) - 2022 Q1 - Quarterly Report
2022-05-05 11:34
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Karyopharm Therapeutics Inc. (Exact name of registrant as specified in its charter) (State or other jur ...